Xenon Pharmaceuticals
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Xenon Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).
Xenon Pharmaceuticals: 13 sponsored US clinical trials, 5 recruiting.
Xenon Pharmaceuticals sponsors 13 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 5 completed. 8 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Focal Onset Seizures, with 2 trials.
Top-decile sponsor footprint
Xenon Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
13 total, page 1 of 1
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
NCT07172516
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
NCT07076407
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
NCT06775379
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
NCT05716100
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
NCT05667142
A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy
NCT03796962
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
NCT05614063
A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder
NCT05376150
An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE
NCT04912856
XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy
NCT04639310
Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia
NCT01486446
A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)
NCT01195636
Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction
NCT00954356
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 4 |
| Phase 3 | 8 |
Where Xenon Pharmaceuticals enrollment is open (later-stage tilt)
5 recruiting of 13 indexed (38% open); 5 completed (38%).
Phase mix: 8 late (III/IV) vs 5 early (I/II) (later-stage heavy).
Top condition: Focal Onset Seizures (2 trials), 8 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Xenon Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 13 registered trials and 38% open enrollment, not the therapeutic-area sidebar.
Xenon Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 13 trials (± recruiting share)
- Adaptimmune · 13 trials · 0% recruiting
- Agennix · 13 trials · 0% recruiting
- Akili Interactive Labs · 13 trials · 0% recruiting
- Alumis · 13 trials · 8% recruiting
Sponsors near 38% open enrollment (± trial volume)
- Morehouse School of Medicine · 38% recruiting · 13 trials
- Northeastern University · 38% recruiting · 39 trials
- Thomas Hope · 38% recruiting · 13 trials
- William Stoops · 38% recruiting · 13 trials
Related
What to do with this Xenon Pharmaceuticals page
13 registered trials is a research-attention snapshot, not an endorsement of Xenon Pharmaceuticals or any single study.
- 5 of Xenon Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Focal Onset Seizures is the condition Xenon Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Focal Onset Seizures trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Xenon Pharmaceuticals pipeline card: 13 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.